1 / 43

Anti Hypertensive Drugs

Anti Hypertensive Drugs. Dr.hasem mansour. Drugs used to treat Hypertension. HTN = BP > 140/90 complications: premature death vascular disease of brain, heart,kidneys. Goal of treatment. Improve life expectancy. Preventing cardiovascular problems by reducing BP < 140/90

kwhitley
Télécharger la présentation

Anti Hypertensive Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Anti Hypertensive Drugs Dr.hasemmansour

  2. Drugs used to treat Hypertension • HTN = BP > 140/90 • complications: premature death vascular disease of brain, heart,kidneys

  3. Goal of treatment • Improve life expectancy. • Preventing cardiovascular problems by reducing BP < 140/90 • Prevent cerebrovascular accidents and kidney damage

  4. Initial treatment of hypertension • Lifestyle modification first including exercise. • No smoking • Weight control • Reduce alcohol intake • Decrease stress • Sodium control

  5. Drugs to treat hypertension • Diuretics • Calcium channel blockers • Angiotesin converting enzyme inhibitors (ACEI). • Angiotensin receptor blockers (ARB). • Autonomic nervous system agents • Direct acting vasodilators

  6. Diuretics action • Thiazide diuretics, such as hydrochlorothiazide lower blood pressure by increasing sodium and water excretion. • This causes in extracellular volume, resulting in cardiac output & renal blood flow . • The net result is hypotensive.

  7. The Nephron

  8. Loop diuretics • The loop diuretics (furosemide) • Block sodium and chloride reabsorption in the kidneys, even in patients with poor renal function. • The net result hypotension.

  9. Diuretics use • Treatment mild to moderate HTN • First drug of treatment is thiazide. • Treatment heart failure or kidney disease(loop diuretics). • Reduce edema associated with CHF (loop diuretics).

  10. Diuretics side effects • Loop diuretics: ototoxicity, blood dyscriasis, hypokalemia, hyperurecemia, hypotension. • Thiazide diuretics: Hypokalemia, headache, hepatotoxicity, hyperglycemia , hypotension and hyperurecemia.

  11. Potassium sparing diuretics • Spironolactone (inhibits sodium transport at the late distal and collecting ducts) • Spironolactone prevent potassium loss. • Used to treat resistant HTN • Used in combination with other diuretic.

  12. Side effects • Orthostatic hypotension • Dry mouth, irritation • Hyperkalemia • Disorientation • Dehydration • Gynecomastia

  13. Calcium Channel Blockers • Block the inward movement of calcium in the heart and in smooth muscle of the peripheral arteriolar vasculature. • This causes smooth muscle to relax, dilating mainly arterioles.

  14. Calcium Channel Blockers types • Non dihydropyridine: Verapamil and Diltiazem • Have a much greater affinity for heart. • Dihydropyridines: nifedipine , amlodipine. • Have a much greater affinity for vascular calcium channels.

  15. SIDE EFFECTS • Decrease BP • Bradycardia extremely • May precipitate A-V block • Headache, flushing and dizziness • Abdominal discomfort • Peripheral edema • Constipation with verapamil

  16. ACE INHIBITORS • Captopril, enalapril • ACE inhibitors decrease angiotensin II causing Vasodilation of both arterioles and veins. • Also decrease sodium and water retention. • ACE inhibitors reduce cardiac work

  17. ACEI and ARB mechanism of action

  18. Therapeutic uses • Treatment of HTN. • Prevention of ventricular remodeling after MI. • ACE inhibitors are first-line drugs for treating heart failure, hypertensive patients with chronic kidney disease. • ACE inhibitors slow the progression of diabetic nephropathy.

  19. Side effects • Headache • Rash, angioedema • Orthostatic hypotension-infrequent • Dry Cough 10- 20 % of pts. • GI distress and disturbance of taste. • Hyperkaleemia • Need frequent monitoring of renal function

  20. ANGIOTENSIN II RECEPTOR BLOCKERS • The ARBs, such as losartan and valsartan are alternatives to the ACE inhibitors. • Their pharmacologic effects, use are similar to those of ACE inhibitors • Adverse effects are similar to those of ACE inhibitors, except the risks of cough and angioedema are significantly decreased.

  21. ACEI and ARB • These agents are also teratogenic and should not be used by pregnant women.

  22. Adrenergic receptors • Sympathetic Nervous System • Alpha 1 = vasoconstriction • Alpha 2 = vasodilation • Beta 1 = increases heart rate • Beta 2 = bronchodilation

  23. Mechanism of action of B blockers • Blockade of β1-adrenoceptors in heart reduces heart rate and myocardial contractility. • Carvedilol and labetalol also block a-receptors and produce vasodilation.

  24. Therapeutic uses • The primary therapeutic benefits of β-blockers are seen in hypertensive patients with concomitant heart disease, such as • Arrhythmia : (atrial fibrillation), • Previous myocardial infarction, angina pectoris, and chronic heart failure.

  25. Side effects • Bradycardia, AV block • Intermittent claudication. • Bronchospasm, wheezing • Hypoglycemia. • Heart failure: edema,dyspnea • Insomnia • Fatigue • Sexual dysfunction

  26. Alpha-1 Adrenergic Blocking Agents • Block postsynaptic alpha-1 adrenergic receptors to produce arteriolar and venous vasodilation • Reduces peripheral-vascular resistance

  27. Side effects • Drowsiness • Headache • Dizziness,tachycardia,fainting • Weakness,lethargy • Palpitation. • Pancreatitis.

  28. Centrally Acting Alpha-2 Agonists • Stimulate Alpha-2 receptors in brainstem • Decreases HR, SBP and DBP • More frequent side effects – drowsiness, dry mouth, dizziness • Never suddenly stop = rebound HTN • Clonidine. • Methyldopa : the safest drug in pregnancy

  29. Renin IV: V: Resistant HT / Intolerance Add / substitute alpha blocker Re-consider 20 causes  trial of spironolactone AB/CD Rule – HT Treatment ACEi, Beta-blocker Ca++-blocker, Diuretic) (AB/CD = AGE Younger (< 55) High Renin HT Older (> 55) Low Renin HT I ACEi BB CCB Diuretic I III III A + B A + B + D D + C + A II D + C II Dickerson et al. Lancet 353:2008-11;1999

  30. CLINICAL RELEVANCE FOR REHABILITATION • Adverse Drug Reactions • • Orthostatic hypotension is a common problem with • some classes of antihypertensive. • • Broncho constriction is a problem with beta-receptor • antagonists. • • Beta-receptor antagonists blunt the early manifestations • of hypoglycemia. • Loop and thiazide diuretics can cause hypokalemia. • • Potassium-sparing diuretics and ACEI can cause hyperkalemia.

  31. Effects Interfering with Rehabilitation • Orthostatic cause patients to faint when position change, exiting from a warm aquatherapy area, or if aerobic exercise is terminated without an appropriate cool-down period. • Dyspnea may decrease aerobic capacity. • Manifestations of hypoglycemia occurring during aerobic activities may be delayed. • Cardiac output may be depressed during aerobic activities by several drug groups. • Altered plasma potassium levels can cause paresthesias, decrease skeletal muscle function, increase cramps, and increase the risk of cardiac dysfunction.

  32. Possible Therapy Solutions • • Check blood pressure and heart rate prior to and following aerobic activities. • • Monitor heart rate during aerobic activities. • • To prevent fainting associated with orthostatic hypotension , assist patients with positional changes and when exiting a warm pool. • Always provide a cool-down period following exercise. • • Allow increased time to complete aerobic tasks to prevent dyspnea and account for depressed cardiac activity.

  33. Possible Therapy Solutions • Use percievedexertion ( Borg rating of Perceived Exertion Scale) when determining aerobic activityin patients being treated with beta– receptor antagonists. • Check glucose levels prior to aerobic activities if the patients are taking hypoglycemic drugs. • Review the clinical manifestations of altered plasma potassium levels and determine if patients are taking medications that may alter these levels.

More Related